Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA OTC Funding Increase For ’04 Trimmed By House Appropriations Cmte.

This article was originally published in The Tan Sheet

Executive Summary

Funding for FDA nonprescription drug activities would increase $700,000 under the FY 2004 Agriculture Appropriations bill reported out of the House Appropriations Committee June 25

You may also be interested in...



FDA Announces “Proactive” Approach To Rx-To-OTC Switches

FDA plans to take a more active role in initiating Rx-to OTC switches in coming years, Senior Associate Commissioner for Management & Systems Jeff Weber said Feb. 3

Washington In Brief

Burton gets subcommittee chair: Former House Government Reform Committee Chair Dan Burton (R-Ind.) named to oversee newly created Subcommittee on Wellness & Human Rights, Committee Chair Tom Davis (R-Va.) announces Jan. 31. Subcommittee will address issues concerning public health policy, human rights and family health, according to Davis' office. Votes to confirm the subcommittee and chairman appointment will be taken when the full Government Reform Committee convenes, possibly the week of Feb. 10. In his new position, Burton likely will revisit dietary supplement-related issues, which were the subject of frequent hearings during his tenure as full committee chair...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel